COLOGNE, Germany--(BUSINESS WIRE)--CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced a collaboration agreement with Généthon (Evry, France) for the development and exploitation of lentivirus packaging cell lines based on CEVEC's proprietary CAP(R)GT technology. Under the terms of the agreement, CEVEC will grant Généthon a license for the development of lentivirus packaging cell lines based on CEVEC